ClinicalTrials.gg
CompletedNCT00532506Updated Oct 10, 2008

Phase II Dose-Finding Study of SK-0403 With Type 2 Diabetes Mellitus

A Phase 2 interventional study of SK-0403 in Type 2 Diabetes Mellitus, sponsored by Sanwa Kagaku Kenkyusho Co., Ltd.. Completed at 10 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2008-10-10.

Sponsored by Sanwa Kagaku Kenkyusho Co., Ltd. · Phase 2 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Allocation
Randomized
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 394 studies in Diabetes Mellitus, Type 2 with a site in Japan — 23 open to participants now, 31 under way, 22 of them phase 3. Diabetes Mellitus, Type 2 · Japan.

Phase 2
44 of 394
3 open now
Registered
44th of 394
by date

Among the 394 studies in Diabetes Mellitus, Type 2 with a site in Japan, this one is one of 44 in phase 2, and was the 44th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

23 of the 394 studies in Diabetes Mellitus, Type 2 with a site in Japan are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 20 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 394 studies in Diabetes Mellitus, Type 2 with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the clinical efficacy and safety of SK-0403 in patients with Type2 Diabetes Mellitus

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Treatment-naive subjects diagnosed with type 2 diabetes mellitus
  • Stable diet program for at least 8 weeks
  • Criteria for are met

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes
  • Patients treated with other antidiabetic drugs or Insulin
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double

Interventions

06

Study locations

10 sites
  • Fukuoka, Japan
  • Gifu, Japan
  • Gunma, Japan
  • Hokkaido, Japan
  • Ibaragi, Japan
  • Kanagawa, Japan
  • Kumamoto, Japan
  • Oita, Japan
  • Okinawa, Japan
  • Tokyo, Japan
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 10, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00532506
Lead sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
First posted
Sep 20, 2007
Last update
Oct 10, 2008

Study contacts

Ryuzo Kawamori, M.D.
study chair · Juntendo University School of Medicine, Dept. of Endocrinology and Metabolism
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anagliptin

Start the discussion